Devgen’s product opportunities each have their foundation in a specific competitive lead of the company’s technology and intellectual property.

Devgen’s core technology edge today includes powerful RNAi tools to discover pest control and human drug targets, proprietary solutions for compound screening of targets, and RNAi-based, protein- and chemistry-based platforms to generate crop protection traits and candidate human drugs.

Devgen’s competitive edge is based on its technology platform using the model organism C. elegans. This small nematode worm is a powerful experimental tool to efficiently unravel biological processes. The use of this organism to study biology has led to a deeper understanding of human disease and new concepts for therapeutic intervention as well as to the discovery of RNA interference, which has significant applications in pharmaceutical and agricultural research and development. Devgen industrialized the use of C. elegans as a discovery tool for the pharmaceutical and crop protection industries by developing a portfolio of technologies to identify drug targets and solutions for compound screening of targets. In addition, the company developed the concept of using the RNAi mechanism to provide a new generation of biotech crop protection solutions.

Devgen has consistently evolved its organization and
technology base downstream to build high value product-oriented programs: the company complemented its C. elegans platform with advanced genomics and protein technologies, high-throughput screening, biology and medicinal chemistry capabilities to support focused product design and development for the agro-chemical, seed and pharmaceutical industries.